PolyPeptide Group AG
SIX:PPGN
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
14.19
34.4
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CHF.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
PolyPeptide Group AG
PolyPeptide Group AG
Cash & Cash Equivalents
PolyPeptide Group AG
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
PolyPeptide Group AG
SIX:PPGN
|
Cash & Cash Equivalents
€95.7m
|
CAGR 3-Years
77%
|
CAGR 5-Years
57%
|
CAGR 10-Years
N/A
|
|
|
Bachem Holding AG
SIX:BANB
|
Cash & Cash Equivalents
CHf62.7m
|
CAGR 3-Years
46%
|
CAGR 5-Years
39%
|
CAGR 10-Years
10%
|
|
|
Siegfried Holding AG
SIX:SFZN
|
Cash & Cash Equivalents
CHf64.5m
|
CAGR 3-Years
3%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
|
Lonza Group AG
SIX:LONN
|
Cash & Cash Equivalents
CHf1.2B
|
CAGR 3-Years
34%
|
CAGR 5-Years
24%
|
CAGR 10-Years
16%
|
|
|
Tecan Group AG
SIX:TECN
|
Cash & Cash Equivalents
CHf108.3m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
N/A
|
|
|
SKAN Group AG
SIX:SKAN
|
Cash & Cash Equivalents
CHf85.1m
|
CAGR 3-Years
10%
|
CAGR 5-Years
191%
|
CAGR 10-Years
N/A
|
|
PolyPeptide Group AG
Glance View
PolyPeptide Group AG is a contract development and manufacturing organization for clinical and approved commercial-stage peptide drug substances used in peptide-based therapeutics. The company is headquartered in Zug, Zug and currently employs 1,041 full-time employees. The company went IPO on 2021-04-29.
See Also
What is PolyPeptide Group AG's Cash & Cash Equivalents?
Cash & Cash Equivalents
95.7m
EUR
Based on the financial report for Dec 31, 2023, PolyPeptide Group AG's Cash & Cash Equivalents amounts to 95.7m EUR.
What is PolyPeptide Group AG's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
57%
Over the last year, the Cash & Cash Equivalents growth was 155%. The average annual Cash & Cash Equivalents growth rates for PolyPeptide Group AG have been 77% over the past three years , 57% over the past five years .
You don't have any saved screeners yet